Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals
I-CRECT
Interventions to Decrease Carbapenem Resistant Enterobacteriaceae Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals
1 other identifier
interventional
800
1 country
1
Brief Summary
Carbapenem resistant Enterobacteriaceae (CRE) colonization of patients discharged from hospitals is a source of transmission to the community. In a cluster randomized controlled trial the effect of a bundle of interventions will be assessed on CRE transmission from CRE+ index patient discharged from hospital to HouseHold (HH) members. The districts in two provinces will be randomized to intervention or control. An information, communication, education and hygiene intervention, developed in collaboration with local health authorities, will aim to improve hygiene and decrease antibiotic (AB) use. The effect will be evaluated on CRE transmission between HH members, livestock and environment through consecutive CRE screening using fecal and hospital effluent samples cultured on carbapenem selective media. Knowledge, Attitudes, Practice surveys with smartphones will assess health seeking, AB use and hygiene adherence, hence detecting the effect of interventions. If transmission of CRE +/- Colistin Resistant Enterobacteriaceae (CoRE, common among livestocks) is detected the source will be investigated including livestock and food, targeted information will be given and evaluated. In hospitals the effect of cohort care will be assessed on CRE acquisition, hospital acquired infection, treatment outcome, costeffectiveness and contamination in sewage water. Mechanisms of resistance, relatedness of CRE isolates in different One Health departments, and rate of CRE transmission from humans to animals and vice versa, will be assessed through Whole Genome Sequencing (WGS).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2022
CompletedFirst Submitted
Initial submission to the registry
May 4, 2023
CompletedFirst Posted
Study publicly available on registry
May 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
ExpectedJune 24, 2025
June 1, 2025
3.5 years
May 4, 2023
June 18, 2025
Conditions
Outcome Measures
Primary Outcomes (5)
Change the prevalence of CRE colonisation
The intervention at hospital will lead to the reduction of CRE colonisation, hospital acquire infection, treatment duration and costs.
12 months from the starting of recruitment patients
Cheng th prevalence of CRE transmission in the household
The Household Education Communication Hygiene Intervention expected to reduce the transmission of CRE from index patient to household member.
12 months from the starting of recruitment community participants
Change the awareness regarding AMR of local people
The understanding on AMR, particularly of CRE, proper use of antibiotic for both humans and animals, will be improved. This will be measured through the quantitative questionnaires.
18 months from the starting of recruitment community participants
Assessment the effectiveness of the hospital wastewater treatment on reducing CRE from hospital to community
The presence of CRE in hospital wastewater before and after treatment will be compared to evaluate the effectiveness of the treatment system on preventing the spreading of AMR to the community.
24 months from the starting of the project
Investigate the genetic relatedness of CRE isolates from hospital, household, animals, wastewater
The CRE isolated from rectal swab of patient admitted to hospital, household members, animals and wastewater will be subjected to Whole Genome Sequencing using Oxford MinION Nanopore/Illumina Miseq sequencing and bioinformatics analysis to investigate the mechanisms of resistance in different One-Health compartments.
24 months from the starting of the project
Study Arms (2)
Intervention district
ACTIVE COMPARATORAn information, communication, education and hygiene intervention, developed in collaboration with local health authorities, will aim to improve hygiene and decrease antibiotic use.
cohort care at the hospital
ACTIVE COMPARATORA laminated note (yellow for "suspicious CRE carrier": green for (CRE-) patients and red for (CRE+) patients) should be put on the front of the patients' bed.
Interventions
There will be 3 different cohort groups for the patients: 1) Unknown CRE colonisation status with increased barrier precautions (all patients until screening results arrive will belong to this group unless there are available screening results from referral hospital), 2) CREpos, and 3) CREneg. CREpos patients (2) will be treated in one area of the ICUs by specially assigned nurses/personnel.
The intervention will focus on two main measurable outcomes: 1) Decrease feco-oral-animal transmission route to prevent in-HH and community spread of CRE +/- CoRE. 2) Decrease unindicated community use of ABs for humans and animals. This WP focuses on a one health intervention in collaboration with local health authorities, developing and implementing an HH Education Communication Hygiene Intervention (HECHI) to improve HH hygiene and health management and reduce the risk of transmission between humans and animals, a Provider Engagement Intervention (PEI) to improve case management of common infection and decrease unindicated AB, and and a Livestock AB Intervention (LAI) to reduce the use of AB in livestock through improved biosecurity conditions and animal husbandry.
Eligibility Criteria
You may qualify if:
- All patients under 2 years old at the selected hospital are highly appreciated to join the study.
You may not qualify if:
- Patients not from the selected hospital and individuals outside the selected province
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hanoi University of Public Healthlead
- Linkoeping Universitycollaborator
- Karolinska Institutetcollaborator
- Universität Tübingencollaborator
- University of Copenhagencollaborator
- National Children's Hospital, Vietnamcollaborator
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD)collaborator
- International Centre for Antimicrobial Resistance Solutionscollaborator
Study Sites (1)
Thai Binh Pediatric Hospital
Thái Bình, Thai Binh, 06122, Vietnam
Study Officials
- PRINCIPAL INVESTIGATOR
Mattias Larsson, MD
Karolinska Institutet
- PRINCIPAL INVESTIGATOR
Thirumalaisamy Velavan, PhD
University of Tübingen, Germany
- STUDY DIRECTOR
Håkan Hanberger
Linkoeping University
- PRINCIPAL INVESTIGATOR
Flavie Goutard, PhD
CIRAD, France
- PRINCIPAL INVESTIGATOR
Yaovi Mahuton Gildas Hounmanou, PhD
University of Copenhagen
- PRINCIPAL INVESTIGATOR
Minh-Dien Tran
Vietnam National Children's Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy Director of Center for Public Health and Ecosystem Research
Study Record Dates
First Submitted
May 4, 2023
First Posted
May 23, 2023
Study Start
July 1, 2022
Primary Completion
December 31, 2025
Study Completion (Estimated)
June 30, 2026
Last Updated
June 24, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share